A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | MicrobiomeTrials
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-07-01Est. Completion: 2027-12-31
Enrollment target: 35 participants
Locations
Children's Hospital Los Angeles, Los Angeles, California, United States
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Children's National, Washington D.C., District of Columbia, United States
University of Florida, Gainesville, Florida, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Memorial Sloan Kettering, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Texas Children's Hospital, Houston, Texas, United States
Hospital for Sick Children, Toronto, Ontario, Canada
Other microbiome trials you might be interested in